Anti-Infection

Total Page:16

File Type:pdf, Size:1020Kb

Anti-Infection Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com Anti-infection Anti-infectives are drugs that can either kill an infectious agent or inhibit it from spreading. Anti-infectives include antibiotics and antibacterials, antifungals, antivirals and antiprotozoals. Antibiotics specifically treat infections caused by bacteria, most commonly used types of antibiotics are: Aminoglycosides, Penicillins, Fluoroquinolones, Cephalosporins, Macrolides, and Tetracyclines. New other approaches such as photodynamic therapy (PDT) and antibacterial peptides have been considered as alternatives to kill bacteria. The high rates of morbidity and mortality caused by fungal infections are associated with the current limited antifungal arsenal and the high toxicity of the compounds. The most common antifungal targets include fungal RNA synthesis and cell wall and membrane components, though new antifungal targets are being investigated. Viral infections occur when viruses enter cells in the body and begin reproducing, often causing illness. Viruses are classified as DNA viruses or RNA viruses, RNA viruses include retroviruses, such as HIV, are prone to mutate. The currently available antiviral drugs target 4 main groups of viruses: herpes, hepatitis, HIV and influenza viruses. Drug resistance in the clinical utility of antiviral drugs has raised an urgent need for developing new antiviral drugs. Antiprotozoal drugs are medicines that treat infections caused by protozoa. Of which, malaria remains a major world health problem following the emergence and spread of Plasmodium falciparum that is resistant to the majority of antimalarial drugs. At present, antimalarial discovery approaches have been studied, such as the discovery of antimalarials from natural sources, chemical modifications of existing antimalarials, the development of hybrid compounds, testing of commercially available drugs that have been approved for human use for other diseases and molecular modelling using virtual screening technology and docking. References: [1] Scorzoni L, et al. Front Microbiol. 2017 Jan 23;8:36. [2] Dehghan Esmatabadi MJ, et al. Cell Mol Biol (Noisy-le-grand). 2017 Feb 28;63(2):40-48. [3] Raymund R, et al. Mayo Clin Proc. 2011 Oct; 86(10):1009-1026. www.MedChemExpress.com 1 2 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com Target List in Anti-infection • Arenavirus 3 • Bacterial 6 • CMV 62 • Enterovirus 65 • Filovirus 67 • Fungal 69 • HBV 82 • HCV 86 • HIV 96 • HSV 110 • Influenza Virus 113 • Parasite 118 • Reverse Transcriptase 135 • RSV 140 • SARS-CoV 143 www.MedChemExpress.com 3 Arenavirus An arenavirus is a virus which is a member of the family Arenaviridae. These viruses infect rodents and occasionally humans. Arenaviruses are a diverse family of small, enveloped, single-stranded RNA viruses which are generally propagated through asymptomatic, chronic infection of specific rodent hosts. Several arenaviruses are significant human pathogens, including five distinct hemorrhagic fever viruses designated category A by the CDC and NIAID, which is indicative of the level of highest threat to civilian populations. Several arenaviruses, including Lassa virus (LASV), are causative agents of hemorrhagic fever, for which effective therapeutic options are lacking. The convergence of sensitivity to diverse small-molecule inhibitors thus identifies a robust new target for arenavirus antiviral discovery within the viral entry phase. 4 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Arenavirus Inhibitors & Modulators GP(33-41) LHF-535 Cat. No.: HY-P0323 Cat. No.: HY-112762 Bioactivity: GP(33-41), a 9-aa-long peptide, is the optimal sequence of the Bioactivity: LHF-535 is an antiviral agent extracted from patent GP1 epitope of lymphocytic choriomeningitis virus, and can WO2013123215A2, Compound 38, has EC 50s of <1 μM, <1 b upregulate H-2D molecules at the RMA-S (Db Kb) cell surface μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg [1] with SC 50 of 344 nM. virus, respectively . Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg ST-193 ST-193 hydrochloride Cat. No.: HY-101441 Cat. No.: HY-101441A Bioactivity: ST-193 is a potent broad-spectrum arenavirus inhibitor; Bioactivity: ST-193 hydrochloride is a potent broad-spectrum arenavirus inhibits Guanarito, Junin, Lassa and Machupo virus with IC50 inhibitor; inhibits Guanarito, Junin, Lassa and Machupo virus with IC values of 0.44, 0.62, 1.4 and 3.1 nM, respectively. values of 0.44, 0.62, 1.4 and 3.1 nM, respectively. 50 Purity: 99.78% Purity: 98.22% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg www.MedChemExpress.com 5 Bacterial Anything that destroys bacteria or suppresses their growth or their ability to reproduce. Heat, chemicals such as chlorine, and antibiotic drugs all have antibacterial properties. Many antibacterial products for cleaning and handwashing are sold today. Such products do not reduce the risk for symptoms of viral infectious diseases in otherwise healthy persons. This does not preclude the potential contribution of antibacterial products to reducing symptoms of bacterial diseases in the home. 6 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Bacterial Inhibitors & Modulators (+)-(3R,8S)-Falcarindiol (+)-Camphor ((3R,8S)-Falcarindiol; 3(R),8(S),9(Z)-Falcarindiol) Cat. No.: HY-N1976 (D-(+)-Camphor; (1R)-(+)-Camphor) Cat. No.: HY-B1173 Bioactivity: (+)-(3R,8S)-Falcarindiol is a polyacetylene found in carrots, Bioactivity: (+)-Camphor is an ingredient in cooking, and as an embalming has antimycobacterial activity, with an IC 50 of 6 μM and fluid for medicinal purposes, MIC of 24 μM against Mycobacterium tuberculosis H37Ra [1] [2]. Antineoplastic and anti-inflammatory activity [2]. Purity: >98% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg Size: 10mM x 1mL in DMSO, 1 g (+)-Viroallosecurinine (R)-Ofloxacin Cat. No.: HY-N5002 (Dextrofloxacin) Cat. No.: HY-B0330D Bioactivity: (+)-Viroallosecurinine, isolated from Securinega virosa as a Bioactivity: (R)-Ofloxacin (Dextrofloxacin) is an antibiotic useful for the cytotoxic alkaloid, exhibits a MIC of 0.48 μg/mL for Ps. treatment of a number of bacterial infections [1]. [1] [1] Aeruginosa and Staph. aureus . Antibacterial activity . Antibacterial activity [1]. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg, 10 mg Size: 5 mg 2-(Methylamino)-1H-purin-6(7H)-one 4(3H)-Quinazolinone (N2-methylguanine) Cat. No.: HY-101412 Cat. No.: HY-W018800 Bioactivity: 2-(Methylamino)-1H-purin-6(7H)-one (N2-Methylguanine) is a Bioactivity: 4(3H)-Quinazolinone is a building block in chemical synthesis. modified nucleoside. 2-(Methylamino)-1H-purin-6(7H)-one is an Biologically active nitrogen heterocyclic compounds. Possesses endogenous methylated nucleoside found in human fluids. a wide spectrum of biological properties like antibacterial, antifungal, anticonvulsant, anti-inflammatory, anti-HIV, anticancerous and analgesic activities [1] [2]. Purity: 98.0% Purity: 97.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg, 100 mg Size: 10mM x 1mL in DMSO, 100 mg 4-(tert-Butyl)-benzhydroxamic Acid 4-Chlorosalicylic acid Cat. No.: HY-114818 Cat. No.: HY-W016867 Bioactivity: 4-(tert-Butyl)-benzhydroxamic Acid is a PqsR antagonist with Bioactivity: 4-Chlorosalicylic acid is a pharmaceutical intermediate. Inhibits monophenolase and diphenolase activity with IC s IC50s of 12.5 μM and 23.6 μM for E. coli and P. aeruginosa, 50 respectively. 4-(tert-Butyl)-benzhydroxamic Acid reduces the of 1.89 mM and 1.10 mM. Potent antimicrobial activity. Against production of the virulence factor pyocyanin in P. aeruginosa<… E. coli with the MIC of 250 μg/mL and with the MBC of 500 μg/… Purity: >98% Purity: 99.95% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: Size: 10mM x 1mL in DMSO, 100 mg 4-Hydroxybenzoic acid 5-hydroxypyrazine-2-carboxylic acid Cat. No.: HY-Y0264 Cat. No.: HY-76210 Bioactivity: 4-Hydroxybenzoic acid, a phenolic derivative of benzoic acid, Bioactivity: 5-hydroxypyrazine-2-carboxylic acid , a metabolite of could inhibit most gram-positive and some gram-negative anti-tuberculosis drug pyrazinamide (PZA). bacteria, with an IC50 of 160 μg/mL. Purity: 98.0% Purity: 99.99% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 g 1 g www.MedChemExpress.com 7 6-Amino-5-azacytidine 7-Aminocephalosporanic acid Cat. No.: HY-111643 (7-ACA) Cat. No.: HY-B1434 Bioactivity: 6-Amino-5-azacytidine inhibits the growth of bacteria E. coli Bioactivity: 7-Aminocephalosporanic acid is the core chemical structure for [1]. the synthesis of cephalosporin antibiotics, is a potent β-lactamase inhibitor. Purity: >98% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in Water, Size: 100 mg 10 mg A7132 AAI101 Cat. No.: HY-U00225 Cat. No.: HY-103095 Bioactivity: A7132 is an antibacterial agent. A7132 possess broad and Bioactivity: AAI101 is an extended-spectrum β-lactamase inhibitor, against potent antibacterial activity. many resistant Gram-negative pathogens. Purity: >98% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 250 mg, 500 mg Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Acetohydroxamic acid Acetylazide (AHA) Cat. No.: HY-B1235 (Acetylkelfizina; Acetylsulfamethoxypyrazine; FI6073) Cat. No.: HY-101575 Bioactivity: Acetohydroxamic acid is a potent and irreversible inhibitor of Bioactivity: Acetylazide is a synthetic broad-spectrum bacteriostatic bacterial and plant urease and also used as adjunctive therapy antibiotic.
Recommended publications
  • A Multicenter, Multi-Outbreak, Randomized, Controlled Safety And
    2018 Ebola MCM RCT Protocol Page 1 of 92 IND#: 125530 CONFIDENTIAL 4 October 2019, version 7.0 A Multicenter, Multi-Outbreak, Randomized, Controlled Safety and Efficacy Study of Investigational Therapeutics for the Treatment of Patients with Ebola Virus Disease Short Title: 2018 Ebola MCM RCT Protocol Sponsored by: Office of Clinical Research Policy and Regulatory Operations (OCRPRO) National Institute of Allergy and Infectious Diseases 5601 Fishers Lane Bethesda, MD 20892 NIH Protocol Number: 19-I-0003 Protocol IND #: 125530 ClinicalTrials.gov Number: NCT03719586 Date: 4 October 2019 Version: 7.0 CONFIDENTIAL This document is confidential. No part of it may be transmitted, reproduced, published, or used by other persons without prior written authorization from the study sponsor and principal investigator. 2018 Ebola MCM RCT Protocol Page 2 of 92 IND#: 125530 CONFIDENTIAL 4 October 2019, version 7.0 KEY ROLES DRC Principal Investigator: Jean-Jacques Muyembe-Tamfum, MD, PhD Director-General, DRC National Institute for Biomedical Research Professor of Microbiology, Kinshasa University Medical School Kinshasa Gombe Democratic Republic of the Congo Phone: +243 898949289 Email: [email protected] Other International Investigators: see Appendix E Statistical Lead: Lori Dodd, PhD Biostatistics Research Branch, DCR, NIAID 5601 Fishers Lane, Room 4C31 Rockville, MD 20852 Phone: 240-669-5247 Email: [email protected] U.S. Principal Investigator: Richard T. Davey, Jr., MD Clinical Research Section, LIR, NIAID, NIH Building 10, Room 4-1479, Bethesda,
    [Show full text]
  • Neena Valecha1, Deepali Savargaonkar1, Bina Srivastava1, B
    Valecha et al. Malar J (2016) 15:42 DOI 10.1186/s12936-016-1084-1 Malaria Journal RESEARCH Open Access Comparison of the safety and efficacy of fixed‑dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open‑label study Neena Valecha1, Deepali Savargaonkar1, Bina Srivastava1, B. H. Krishnamoorthy Rao2, Santanu K. Tripathi3, Nithya Gogtay4, Sanjay Kumar Kochar5, Nalli Babu Vijaya Kumar6, Girish Chandra Rajadhyaksha7, Jitendra D. Lakhani8, Bhagirath B. Solanki9, Rajinder K. Jalali10, Sudershan Arora10, Arjun Roy10, Nilanjan Saha10, Sunil S. Iyer10, Pradeep Sharma10 and Anupkumar R. Anvikar1* Abstract Background: Chloroquine has been the treatment of choice for acute vivax malaria for more than 60 years. Malaria caused by Plasmodium vivax has recently shown resistance to chloroquine in some places. This study compared the efficacy and safety of fixed dose combination (FDC) of arterolane maleate and piperaquine phosphate (PQP) with chloroquine in the treatment of uncomplicated vivax malaria. Methods: Patients aged 13–65 years with confirmed mono-infection of P. vivax along with fever or fever in the previ- ous 48 h were included. The 317 eligible patients were randomly assigned to receive FDC of arterolane maleate and PQP (n 159) or chloroquine (n 158) for 3 days. Primaquine was given as an anti-relapse measure on day 3 and continued= for 14 consecutive days.= Primary efficacy analysis included assessment of the proportion of aparasitaemic and afebrile patients at 72 h. Safety endpoints were analysis of adverse events, vital signs, laboratory data, and abnor- malities on electrocardiograph. Patients participated in the study for at least 42 days.
    [Show full text]
  • Optumrx Brand Pipeline Forecast
    RxOutlook® 1st Quarter 2019 OptumRx brand pipeline forecast Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug 2019 Possible launch date Ophthalmological DS-300 DS-300 Eton undisclosed SC Filed NDA 2019 unknown N disease anti-sclerostin Evenity romosozumab Amgen Osteoporosis SC Filed NDA 2/2019 Y N monoclonal antibody tetrahydrofolate iclaprim iclaprim Motif Bio Bacterial infections IV Filed NDA 2/13/2019 Y Y dehydrogenase inhibitor tazarotene/ IDP-118 Valeant retinoid/ corticosteroid Psoriasis TOP Filed NDA 2/15/2019 N N halobetasol adenosine deaminase Mavenclad cladribine Merck/ Teva resistant Multiple sclerosis PO Filed NDA 2/15/2019 Y N deoxyadenosine analog Lotemax Gel loteprednol Valeant corticosteroid Ocular inflammation OP Filed NDA 2/25/2019 N N Nex Gen etabonate turoctocog alfa glyco-PEGylated factor NN-7088 Novo Nordisk Hemophilia IV/SC Filed BLA 2/27/2019 Y N pegol VIII derivative selective sphingosine-1 BAF-312 siponimod Novartis phosphate receptor Multiple sclerosis PO Filed NDA 3/1/2019 Y N agonist midazolam midazolam UCB benzodiazepine Seizures Intranasal Filed NDA 3/1/2019 N Y (USL-261) XeriSol glucagon Xeris glucagon analog Diabetes mellitus SC Filed NDA 3/1/2019 N N Glucagon optum.com/optumrx 1 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug dopamine receptor JZP-507 sodium oxybate Jazz Narcolepsy
    [Show full text]
  • Signature Redacted Signature of Author
    Developing VHH-based tools to study Ebolavirus Infection By Jason V. M. H. Nguyen B.S., Biochemistry and Molecular Biology University of California, Santa Cruz, 2012 Submitted to the Microbiology Graduate Program in partial fulfillment of the requirements for the degree of Doctor of Philosophy At the Massachusetts Institute of Technology June 2019 2019 Massachusetts Institute of Technology. All rights reserved. Signature redacted Signature of Author...... .................................................................... V Y' Jason V. M. H. Nguyen Microbiology Graduate Program May 13, 2019 Signature redacted Certified by.............. ................................................................... Hidde L. Ploegh Senior Investigator Boston Children's Hospital It Signature redacted Accepted by....... ......................................................................... Jacquin C. Niles Associate Professor of Biological Engineering Chair of Microbiology Program MASSACHUSETTS INSTITUTE OF TECHNOLOGY JUN 2 12019 1 LIBRARIES ARCHIVES 2 Developing VHH-based tools to study Ebolavirus Infection By Jason V. M. H. Nguyen Submitted to the Microbiology Graduate Program on May 13th, 2019 in partial fulfillment of the requirements for the degree of Doctor of Philosophy ABSTRACT Variable domains of camelid-derived heavy chain-only antibodies, or VHHs, have emerged as a unique antigen binding moiety that holds promise in its versatility and utilization as a tool to study biological questions. This thesis focuses on two aspects on developing tools to study infectious disease, specifically Ebolavirus entry. In Chapter 1, I provide an overview about antibodies and how antibodies have transformed the biomedical field and how single domain antibody fragments, or VHHs, have entered this arena. I will also touch upon how VHHs have been used in various fields and certain aspects that remain underexplored. Chapter 2 focuses on the utilization of VHHs to study Ebolavirus entry using VHHs that were isolated from alpacas.
    [Show full text]
  • Review Article Efforts Made to Eliminate Drug-Resistant Malaria and Its Challenges
    Hindawi BioMed Research International Volume 2021, Article ID 5539544, 12 pages https://doi.org/10.1155/2021/5539544 Review Article Efforts Made to Eliminate Drug-Resistant Malaria and Its Challenges Wote Amelo 1,2,3 and Eyasu Makonnen 1,2 1Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Addis Ababa University, Addis Ababa, Ethiopia 2Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia 3Department of Pharmacology and Toxicology, School of Pharmacy, Jimma University, Jimma, Ethiopia Correspondence should be addressed to Wote Amelo; [email protected] Received 21 January 2021; Accepted 9 August 2021; Published 30 August 2021 Academic Editor: Jane Hanrahan Copyright © 2021 Wote Amelo and Eyasu Makonnen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Since 2000, a good deal of progress has been made in malaria control. However, there is still an unacceptably high burden of the disease and numerous challenges limiting advancement towards its elimination and ultimate eradication. Among the challenges is the antimalarial drug resistance, which has been documented for almost all antimalarial drugs in current use. As a result, the malaria research community is working on the modification of existing treatments as well as the discovery and development of new drugs to counter the resistance challenges. To this effect, many products are in the pipeline and expected to be marketed soon. In addition to drug and vaccine development, mass drug administration (MDA) is under scientific scrutiny as an important strategy for effective utilization of the developed products.
    [Show full text]
  • Microorganisms-07-00521-V2.Pdf
    microorganisms Review Are Community Acquired Respiratory Viral Infections an Underestimated Burden in Hematology Patients? Cristian-Marian Popescu 1,* , Aurora Livia Ursache 2, Gavriela Feketea 1 , Corina Bocsan 3, Laura Jimbu 1, Oana Mesaros 1, Michael Edwards 4,5, Hongwei Wang 6, Iulia Berceanu 7, Alexandra Neaga 1 and Mihnea Zdrenghea 1,7,* 1 Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 8 Babes str., 400012 Cluj-Napoca, Romania; [email protected] (G.F.); [email protected] (L.J.); [email protected] (O.M.); [email protected] (A.N.) 2 The Faculty of Veterinary Medicine, University of Agricultural Sciences and Veterinary Medicine, Calea Mănăs, tur 3-5, 400372 Cluj-Napoca, Romania; [email protected] 3 Department of Pharmacology, Toxicology and Clinical Pharmacology, Iuliu Ha¸tieganuUniversity of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania; [email protected] 4 National Heart and Lung Institute, St Mary’s Campus, Imperial College London, London W2 1PG, UK; [email protected] 5 Medical Research Council (MRC) and Asthma UK Centre in Allergic Mechanisms of Asthma, London W2 1PG, UK 6 School of Medicine, Nanjing University, 22 Hankou Road, Nanjing 210093, China; [email protected] 7 Department of Hematology, Ion Chiricuta Oncology Institute, 34-36 Republicii Street, 400015 Cluj-Napoca, Romania; [email protected] * Correspondence: [email protected] (C.-M.P.); [email protected] (M.Z.) Received: 8 October 2019; Accepted: 31 October 2019; Published: 2 November 2019 Abstract: Despite a plethora of studies demonstrating significant morbidity and mortality due to community-acquired respiratory viral (CRV) infections in intensively treated hematology patients, and despite the availability of evidence-based guidelines for the diagnosis and management of respiratory viral infections in this setting, there is no uniform inclusion of respiratory viral infection management in the clinical hematology routine.
    [Show full text]
  • Airgid - Instructions for Use Im3 Airgid Is a Gelatin Collagen Sponge of Hemostatic Action to Which 5 % Colloidal Silver Is Added
    Airgid - Instructions for Use iM3 Airgid is a gelatin collagen sponge of hemostatic action to which 5 % colloidal silver is added. It facilitates optimum wound treatment when applied to a surgical cavity and can be cut to the required size to fit smaller wound cavities. The evenly porous foam structure absorbs its own weight in blood several times over, promotes thrombocyte aggregation due to the large surface and fills the wound cavity. The plug thus formed has a constant volume, fits snugly and stabilises blood coagulum. This prevents the formation of fissures and secondary cavities which, without iM3 Airgid, could form by contraction of the blood coagulum and trigger infection due to the invasion of contaminated saliva. Does not block the callus formation. iM3 Airgid remains in the wound and completely absorbed within 3-4 weeks. The addition of colloidal silver has an antimicrobial effect and does not develop any body resistance. Unlike other potential antimicrobial additives, colloidal silver cannot be washed away from the sponge so that its insolubility produces a long-lasting depot effect. Gamma-ray sterilisation process finalizes the manufacturing cycle of the product. Composition: One iM3 Airgid Small Animal (10 × 10 × 10 mm) contains: Hardened gelatine Ph. Eur. 13.85 mg. Colloid silver Ph. Eur. 0.73 mg. One iM3 Airgid Equine (20 × 20 × 20 mm) contains: Hardened gelatine Ph. Eur. 110.8 mg. Colloid silver Ph. Eur. 5.8 mg. Indications: • Socket extraction as part of one or two-stage implant placement. • The general treatment of alveoli and wound cavities, e.g. after cystostomies, apical amputations, maxillary sinus perforations, following surgical removal of tumours or retained teeth.
    [Show full text]
  • Overcoming Fluoroquinolone Resistance: Mechanistic Basis of Non- Quinolone Antibacterials Targeting Type Ii Topoisomerases
    OVERCOMING FLUOROQUINOLONE RESISTANCE: MECHANISTIC BASIS OF NON- QUINOLONE ANTIBACTERIALS TARGETING TYPE II TOPOISOMERASES By Elizabeth Grace Gibson Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in Pharmacology May 10, 2019 Nashville, Tennessee Approved: Neil Osheroff, Ph.D. Joey Barnett, Ph.D. Wendell S. Akers, Pharm.D., Ph.D. Sean Davies, Ph.D. Benjamin Spiller, Ph.D. Timothy R. Sterling, M.D. DEDICATION To all my family and church family who have supported and encouraged me over all my years in school. To Him who I put all my trust. Commit your way to the Lord, trust also in Him and He shall bring it to pass. Psalm 37:5 ii ACKNOWLEDGEMENTS I want to first thank my Ph.D. advisor, Dr. Neil Osheroff, for allowing me to work in his laboratory. Thank you for all your support and encouragement and just being an overall great mentor. You really know how to bring us up when we need it or give us an ego check when we get a little high and mighty when things are going well. I appreciate your supportiveness to careers outside academia. I also appreciate that you always have our best interest at heart. To Dr. Joe Deweese, my first research mentor and the one who instilled the love of topoisomerase research. Without your guidance I would not be where I am today. Thank you for introducing me to Neil and his laboratory and helping with the transition from research in your lab to his.
    [Show full text]
  • Rabbit Anti-Marburgvirus (MARV) VLP Pab ELISA Data
    4 Research Court, Suite 300 Rockville, MD 20850 877-411-2041 [email protected] Rabbit anti-Marburgvirus (MARV) VLP pAb ELISA Data: Catalog #: 04-0005 IgG IgG + IgG + Lot #: MMIG201001IBT Dilution MMARV ZEBOV 1:X Antigen Antigen Immunogen: MARV (Musoke strain) Virus-like Particles (VLPs) containing glycoprotein (GP) 1000 3.30 2.66 Nucleoprotein (NP), and viral protein (VP40). 3162 3.07 1.80 10000 2.68 0.89 Description: Protein A purified rabbit polyclonal 31623 1.87 0.37 antibody reactive to MARV VLP raised in New 100000 0.99 0.14 Zealand white rabbits. 316228 0.43 0.05 1000000 0.17 0.02 Supplied: 0.5 mg of antibody is supplied in PBS at a concentration of 5.75 mg/mL. 0.01% Sodium azide has been added. -Antigen is coated on ELISA plates overnight. -Add 200µl blocking buffer then wash wells with Clonality: Polyclonal PBST. -Antiserum is diluted semi-log. Relevance: the filovirus Marburgvirus is a -Incubate antibody for 2 hour. Category A (NIAID) and HHS select agent. -Wash unbound antibodies and add HRP- Recommended Dilutions: conjugated anti-rabbit IgG. -Wash plates and add substrate to develop color for ELISA: Assay-dependent dilution. 20 minutes. WB: Assay-dependent dilution -Read absorbance at 650nm. Amount of color is directly proportional to amount of antibodies. Storage: 2-3 weeks +4oC, -20◦C long term Western Blot Cross Reactivity: Historical data showed some cross-reactivity with Ebola Virus (EBOV) and -Antiserum recognizes Marburg musoke Sudan Virus (SUDV) VLP’s, most likely due to glycoprotein, nucleoprotein, and VP40 antibodies against Baculovirus proteins since the VLP’s were expressed in SF9-Baculovirus system.
    [Show full text]
  • Current and Novel Approaches in Influenza Management
    Review Current and Novel Approaches in Influenza Management Erasmus Kotey 1,2,3 , Deimante Lukosaityte 4,5, Osbourne Quaye 1,2 , William Ampofo 3 , Gordon Awandare 1,2 and Munir Iqbal 4,* 1 West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana, Legon, Accra P.O. Box LG 54, Ghana; [email protected] (E.K.); [email protected] (O.Q.); [email protected] (G.A.) 2 Department of Biochemistry, Cell & Molecular Biology, University of Ghana, Legon, Accra P.O. Box LG 54, Ghana 3 Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra P.O. Box LG 581, Ghana; [email protected] 4 The Pirbright Institute, Ash Road, Pirbright, Woking, Surrey GU24 0NF, UK; [email protected] 5 The University of Edinburgh, Edinburgh, Scotland EH25 9RG, UK * Correspondence: [email protected] Received: 20 May 2019; Accepted: 17 June 2019; Published: 18 June 2019 Abstract: Influenza is a disease that poses a significant health burden worldwide. Vaccination is the best way to prevent influenza virus infections. However, conventional vaccines are only effective for a short period of time due to the propensity of influenza viruses to undergo antigenic drift and antigenic shift. The efficacy of these vaccines is uncertain from year-to-year due to potential mismatch between the circulating viruses and vaccine strains, and mutations arising due to egg adaptation. Subsequently, the inability to store these vaccines long-term and vaccine shortages are challenges that need to be overcome. Conventional vaccines also have variable efficacies for certain populations, including the young, old, and immunocompromised.
    [Show full text]
  • In Vitro Efficacy of Bacterial Cellulose Dressings Chemisorbed with Antiseptics Against Biofilm Formed by Pathogens Isolated from Chronic Wounds
    Supplementary Materials In Vitro Efficacy of Bacterial Cellulose Dressings Chemisorbed with Antiseptics Against Biofilm Formed by Pathogens Isolated from Chronic Wounds Karolina Dydak 1, Adam Junka 1,*, Agata Dydak 2, Malwina Brożyna 1, Justyna Paleczny 1, Karol Fijalkowski 3, Grzegorz Kubielas 4, Olga Aniołek 5 and Marzenna Bartoszewicz 1 1 Department of Pharmaceutical Microbiology and Parasitology, Medical University of Wroclaw, 50-556 Wroclaw, Poland; [email protected] (K.D.); [email protected] (M.B.); [email protected] (J.P.); [email protected] (M.B.) 2 Faculty of Biological Sciences, University of Wroclaw, 51-148 Wroclaw, Poland; [email protected] 3 Department of Microbiology and Biotechnology, Faculty of Biotechnology and Animal Husbandry, West Pomeranian University of Technology, Szczecin, Piastow 45, 70-311 Szczecin, Poland; [email protected] 4 Faculty of Health Sciences, Wroclaw Medical University, 50-996 Wroclaw, Poland; [email protected] 5 Faculty of Medicine, Lazarski University, 02-662 Warsaw, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-889229341 Citation: Dydak, K.; Junka, A.; Dydak, A.; Brożyna, M.; Paleczny, J.; Abstract: Local administration of antiseptics is required to prevent and fight against biofilm-based Fijalkowski, K.; Kubielas, G.; infections of chronic wounds. One of the methods used for delivering antiseptics to infected wounds Aniołek, O.; Bartoszewicz, M. In is the application
    [Show full text]
  • Gonorrhea, Chlamydia, and Syphilis
    2019 GONORRHEA, CHLAMYDIA, AND SYPHILIS AND CHLAMYDIA, GONORRHEA, Dedication TAG would like to thank the National Coalition of STD Directors for funding and input on the report. THE PIPELINE REPORT Pipeline for Gonorrhea, Chlamydia, and Syphilis By Jeremiah Johnson Introduction The current toolbox for addressing gonorrhea, chlamydia, and syphilis is inadequate. At a time where all three epidemics are dramatically expanding in locations all around the globe, including record-breaking rates of new infections in the United States, stakeholders must make do with old tools, inadequate systems for addressing sexual health, and a sparse research pipeline of new treatment, prevention, and diagnostic options. Lack of investment in sexual health research has left the field with inadequate prevention options, and limited access to infrastructure for testing and treatment have allowed sexually transmitted infections (STIs) to flourish. The consequences of this underinvestment are large: according to the World Health Organization (WHO), in 2012 there were an estimated 357 million new infections (roughly 1 million per day) of the four curable STIs: gonorrhea, chlamydia, syphilis, and trichomoniasis.1 In the United States, the three reportable STIs that are the focus of this report—gonorrhea, chlamydia, and syphilis—are growing at record paces. In 2017, a total of 30,644 cases of primary and secondary (P&S) syphilis—the most infectious stages of the disease—were reported in the United States. Since reaching a historic low in 2000 and 2001, the rate of P&S syphilis has increased almost every year, increasing 10.5% during 2016–2017. Also in 2017, 555,608 cases of gonorrhea were reported to the U.S.
    [Show full text]